Enasidenib

What is Enasidenib?

Enasidenib is a prescription medication primarily used in the treatment of specific types of blood cancer. It belongs to a class of drugs known as isocitrate dehydrogenase-2 (IDH2) inhibitors. Marketed under the brand name Idhifa, this medication represents a significant advancement in targeted therapy for patients with a particular genetic alteration. Unlike traditional chemotherapy, Enasidenib works by specifically targeting a mutated protein within cancer cells, aiming to disrupt their growth and promote their maturation into normal, healthy cells.

Its development stems from a deeper understanding of the molecular drivers of certain cancers, offering a more precise approach to treatment with potentially different side effect profiles compared to conventional cytotoxic agents. Patients eligible for Enasidenib therapy typically undergo genetic testing to confirm the presence of the specific mutation it targets.

How Does it Work?

The mechanism of action of Enasidenib is highly specific and central to its efficacy. In certain cancers, particularly **acute myeloid leukemia (AML)**, a genetic mutation can occur in the gene that codes for the isocitrate dehydrogenase-2 (IDH2) enzyme. This **IDH2 mutation** leads to the production of an abnormal, **mutant isocitrate dehydrogenase-2 (IDH2) enzyme**. This mutant enzyme produces an oncometabolite called 2-hydroxyglutarate (2-HG), which accumulates in cells.

The elevated levels of 2-HG interfere with normal cellular differentiation processes, essentially blocking immature myeloid cells (blasts) from maturing into functional blood cells. This blockage contributes to the uncontrolled proliferation of immature cells characteristic of AML.

Enasidenib works by selectively inhibiting this mutant IDH2 enzyme. By blocking its activity, it reduces the production of 2-HG. This reduction allows the immature myeloid cells to resume their normal differentiation pathway, maturing into healthy blood cells and thereby reducing the burden of leukemia cells in the body. This targeted approach minimizes harm to healthy cells that do not possess the IDH2 mutation, leading to a more focused therapeutic effect.

Medical Uses

Enasidenib is specifically indicated for the treatment of adult patients with **relapsed or refractory** **acute myeloid leukemia (AML)** who have an **IDH2 mutation**. This means the medication is used in patients whose AML has either returned after initial treatment (relapsed) or has not responded to previous treatments (refractory).

Before initiating treatment with Enasidenib, it is crucial for patients to undergo a diagnostic test to confirm the presence of the IDH2 mutation. This genetic testing ensures that the patient's leukemia is one that is specifically driven by the mutation that Enasidenib targets, maximizing the potential for a positive response to the therapy. As a targeted agent, Enasidenib offers a valuable option for a subset of AML patients for whom conventional treatments may have limited efficacy, providing a pathway to improved outcomes and quality of life.

Dosage

The recommended dosage of Enasidenib for adult patients with relapsed or refractory AML with an IDH2 mutation is 100 mg taken orally once daily. It can be taken with or without food. Patients should swallow the tablets whole and not chew, crush, or split them. It is important to continue treatment until disease progression or unacceptable toxicity occurs.

If a dose is missed, it should be taken as soon as possible on the same day, unless it is less than 12 hours before the next scheduled dose. In that case, the missed dose should be skipped, and the patient should resume the regular dosing schedule. Double doses should not be taken to make up for a missed dose. Dosage adjustments, interruptions, or discontinuation may be necessary based on individual patient response and the occurrence of side effects, particularly **differentiation syndrome** or severe hyperbilirubinemia. All dosage decisions must be made by a qualified healthcare professional.

Side Effects

Like all medications, Enasidenib can cause side effects, though not everyone experiences them. Common side effects often include nausea, vomiting, diarrhea, fatigue, decreased appetite, and hyperbilirubinemia (increased bilirubin levels in the blood, which can cause jaundice). It is important for patients to report any side effects to their doctor.

A potentially serious side effect associated with Enasidenib is **differentiation syndrome**. This syndrome can be life-threatening if not recognized and managed promptly. Symptoms of differentiation syndrome may include fever, difficulty breathing, unexplained weight gain, peripheral edema (swelling), pleural effusion (fluid around the lungs), pericardial effusion (fluid around the heart), renal dysfunction, and hypotension. Patients and caregivers should be educated on the symptoms of differentiation syndrome and instructed to seek immediate medical attention if they occur. Management often involves temporary interruption of Enasidenib and administration of corticosteroids.

Drug Interactions

Enasidenib is metabolized by various enzymes and transporters, and therefore has the potential to interact with other medications. It is primarily metabolized by CYP3A4 and UGT enzymes, and it is also a substrate for P-glycoprotein (P-gp).

• Strong CYP3A4 Inhibitors and Inducers: Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase Enasidenib exposure, potentially leading to increased side effects. Conversely, strong CYP3A4 inducers (e.g., rifampin, phenytoin) may decrease Enasidenib exposure, potentially reducing its efficacy.
• UGT Inhibitors: Concomitant use with UGT inhibitors (e.g., gemfibrozil, atazanavir) may increase systemic exposure to Enasidenib's metabolites, which could lead to increased toxicity, particularly hyperbilirubinemia.
• P-glycoprotein Substrates: Enasidenib can inhibit P-glycoprotein, meaning it may increase the concentrations of other drugs that are P-gp substrates (e.g., digoxin, dabigatran). Careful monitoring and dose adjustments of such co-administered drugs may be necessary.

Patients should always inform their healthcare provider about all medications, supplements, and herbal products they are currently taking to avoid potential drug interactions.

FAQ

Is Enasidenib a type of chemotherapy?

No, Enasidenib is not traditional chemotherapy. It is a **targeted therapy** that specifically inhibits the mutant IDH2 enzyme found in certain leukemia cells, rather than broadly killing rapidly dividing cells like conventional chemotherapy.

How long will I need to take Enasidenib?

Treatment with Enasidenib is typically continued until your disease progresses or until you experience unacceptable side effects. Your doctor will regularly monitor your condition to determine the appropriate duration of treatment.

What should I do if I suspect I have **differentiation syndrome**?

If you experience symptoms such as fever, difficulty breathing, unexplained weight gain, or swelling, you should contact your doctor immediately or seek emergency medical care. Early recognition and treatment of **differentiation syndrome** are crucial.

Is genetic testing necessary before starting Enasidenib?

Yes, genetic testing is absolutely necessary. Enasidenib is only effective in patients with **acute myeloid leukemia (AML)** who have an **IDH2 mutation**. The test confirms that your leukemia has this specific genetic alteration, making you eligible for this targeted treatment.

Products containing Enasidenib are available through trusted online pharmacies. You can browse Enasidenib-based medications at ShipperVIP or Medicenter.

Summary

Enasidenib represents a significant therapeutic advance for patients with **relapsed or refractory** **acute myeloid leukemia (AML)** harboring an **IDH2 mutation**. As a selective inhibitor of the **mutant isocitrate dehydrogenase-2 (IDH2) enzyme**, it works by reversing the block in cellular differentiation, allowing immature leukemia cells to mature into healthy blood cells. While offering a highly targeted approach with potentially fewer systemic side effects than traditional chemotherapy, it is associated with specific risks, most notably **differentiation syndrome**, which requires prompt recognition and management.

Careful patient selection through genetic testing, diligent monitoring for side effects, and awareness of potential drug interactions are critical for optimizing the safety and efficacy of Enasidenib therapy. This medication provides a vital option for a specific subset of AML patients, improving their prospects for disease control and quality of life.